Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Plauche

Ophthalmology Sherman, TX Medical Doctor

NPI 1871535674 CMS profile 84167

1625 N Highway 75, Sherman, TX 75090

Open in the dashboard

General payments

$19,608

215 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Plauche of Sherman, TX is reported in the CMS Open Payments database as having received $19,608 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,254 35
2024 General $1,972 46
2023 General $1,089 21
2022 General $524 13
2021 General $851 24
2020 General $1,920 40
2019 General $999 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Plauche
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to William Plauche were reported at $12,254. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year William Plauche Ophthalmology median Middle half National median
2019 $999 $258 $104–$655 $163
2020 $1,920 $126 $45–$321 $114
2021 $851 $205 $76–$534 $132
2022 $524 $266 $100–$678 $149
2023 $1,089 $308 $117–$745 $160
2024 $1,972 $340 $127–$846 $164
2025 $12,254 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Bausch & Lomb Americas Inc. $13,357 34 payments
  2. Glaukos Corporation $1,244 19 payments
  3. Ivantis, Inc $1,067 3 payments
  4. Alcon Vision LLC $633 49 payments
  5. Bausch & Lomb, a division of Bausch Health US, LLC $629 18 payments
  6. TissueTech, Inc. $382 30 payments
  7. Johnson & Johnson Surgical Vision, Inc. $293 6 payments
  8. RxSight Inc $252 6 payments
  9. Sight Sciences, Inc. $211 11 payments
  10. Ocular Therapeutix, Inc. $198 2 payments
  11. Other $1,342 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,925 4 payments
  2. Food and Beverage $6,542 206 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $900 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $150 1 payment
  5. Gift $45 1 payment
  6. Honoraria $26 1 payment
  7. Education $21 1 payment
Products named General payments · program years 2019–2025
  1. enVista MX60 IOL Ophthalmology $5,750 1 payment
  2. enVista MX60 IOL Ophthalmology $1,435 9 payments
  3. Hydrus $1,067 3 payments
  4. IC-8 Apthera IOL $930 2 payments
  5. ENVISTA ENVY IOL $409 5 payments
  6. enVista MX60 IOL Ophthalmology $358 7 payments
  7. iDoseTR $333 4 payments
  8. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $252 6 payments
  9. RXSIGHT CONTACT LENS $252 6 payments
  10. RXSIGHT INJECTOR CARTRIDGE $252 6 payments
  11. Other $5,018 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

1,836

Median for Ophthalmology: 891

Drug cost

$102,861

Median for Ophthalmology: $68,233

Branded share of claims

26.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lumigan Bimatoprost Brand 52 $24,063
Prednisolone Acetate Generic 388 $10,780
Simbrinza Brinzolamide/Brimonidine Tart Brand 38 $8,121
Restasis Cyclosporine Brand 13 $7,671
Rocklatan Netarsudil Mesylat/Latanoprost Brand 14 $6,545
Lotemax Sm Loteprednol Etabonate Brand 25 $6,271
Prolensa Bromfenac Sodium Brand 13 $4,829
Travoprost Generic 42 $4,725
Brimonidine Tartrate Generic 230 $4,387
Moxifloxacin Moxifloxacin Hcl Brand 166 $4,265

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$715,564

Of which drugs: $223,303

Medicare patients

1,001

Average age 76

Services billed

7,757

593 women, 408 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 32%
Diabetes 26%
Chronic kidney disease 19%
Atrial fibrillation 18%
Depression 17%
COPD 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept hd, 1 mg J0177 Office 20 352 $92,832
Injection, faricimab-svoa, 0.1 mg J2777 Office 16 2,400 $65,635
Injection, aflibercept, 1 mg J0178 Office 12 56 $37,083

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OZURDEX
  • AbbVie, Inc. $29
$29 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $24
$24 — —
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $21
$21 — 352
XIIDRA
  • Bausch & Lomb Americas Inc. $4
$4 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record